Mario D’Andrea

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona et al. · Journal of Clinical Oncology · 2006 · 333 citations · Full text

Predictive Role of the <i>UGT1A1</i>, <i>UGT1A7</i>, and <i>UGT1A9</i> Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

Erika Cecchin, Federico Innocenti, Mario D’Andrea et al. · Journal of Clinical Oncology · 2009 · 215 citations · Full text

Genetics, Genetic Epidemiology, Pathology +16

Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giampiero Gasparini et al. · Journal of Clinical Oncology · 2009 · 167 citations

Pharmacotherapy, Irinotecan Administered, Infusional Fluorouracil +16

Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine

Massimo Donadelli, Chiara Costanzo, Stefania Beghelli et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2007 · 156 citations

Tumor Biology, Pancreatic Cancer, Medicine +8